AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Industrial Minerals Ltd

0.105

+0.0066.06%

Volume:121.71K

Turnover:12.78K

Market Cap:17.08M

PE:-12.80

High:0.105

Open:0.102

Low:0.102

Close:0.099

52wk High:0.200

52wk Low:0.092

Shares:162.69M

Float Shares:117.64M

Volume Ratio:1.72

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.008

EPS(LYR):-0.008

ROE:-19.12%

ROA:-9.97%

PB:4.09

PE(LYR):-12.80

Loading ...

Overview Company News Filings

Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China

Industrial Minerals Ltd-Response to ASX Aware Query

THOMSON REUTERS

Industrial Minerals Ltd-Application for Quotation of Securities - Ind

THOMSON REUTERS

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline

Industrial Minerals To Acquire Drill Proven Gold Portfolio

BUZZ-Industrial Minerals at 7-month high on Laverton Gold Portfolio acquisition

Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody

Industrial Minerals Ltd-Laverton Gold Project Presentation

THOMSON REUTERS

Industrial Minerals Ltd - Acquisition Valued at a$4.67 Mln in Shares With 2.0% Nsr Royalty

THOMSON REUTERS

Industrial Minerals Ltd - Conducting Two-Tranche Placement of up to a$3 Mln at a$0.10 per Share

THOMSON REUTERS

Industrial Minerals Ltd-Proposed Issue of Securities - Ind

THOMSON REUTERS

BRIEF-Industrial Minerals Seeks Trading Halt

Industrial Minerals Ltd - Trading Halt Pending Proposed Acquisition and Capital Raising Announcement

THOMSON REUTERS

Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs

OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/IND.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","market":"AU","secType":"STK","nameCN":"Industrial Minerals Ltd","latestPrice":0.105,"timestamp":1790835120000,"preClose":0.099,"halted":0,"volume":121711,"delay":0,"changeRate":0.06060606060606052,"nameEN":"Industrial Minerals Ltd","floatShares":117637614,"shares":162690117,"eps":-0.0082,"marketStatus":"Not Yet Opened","change":0.006,"latestTime":"10-01 16:12:00 AEST","open":0.102,"high":0.105,"low":0.102,"amount":12776,"amplitude":0.030303,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0082,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1790899200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.099,"openAndCloseTimeList":[[1790812800000,1790834400000]],"volumeRatio":1.7226976384203583,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IND.AU","preClose":0.11,"auctionPrice":0.105,"auctionVolume":122,"auction":3,"marketStatus":"盘后竞价","timestamp":1790230142616}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","floatShares":117637614,"roa":"-9.97%","roe":"-19.12%","lyrEps":-0.0082,"volumeRatio":1.7226976384203583,"shares":162690117,"dividePrice":0,"high":0.105,"amplitude":0.030303,"preClose":0.099,"low":0.102,"week52Low":0.092,"pbRate":"4.09","psRate":"20409.15","week52High":0.2,"institutionHeld":0,"latestPrice":0.105,"eps":-0.0082,"divideRate":0,"volume":121711,"delay":0,"ttmEps":-0.0082,"open":0.102,"prevYearClose":0.13,"prevWeekClose":0.1,"prevMonthClose":0.099,"prevQuarterClose":0.099,"fiveDayClose":0.105,"twentyDayClose":0.115,"sixtyDayClose":0.125},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2637361871","title":"Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2637361871","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637361871?lang=en_us&edition=fundamental","pubTime":"2026-05-22 09:50","pubTimestamp":1779414600,"startTime":"0","endTime":"0","summary":"NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients. Actair is already commercialized across 21 countries and territories , with further market expansions underway.The IND clearance follows a series of recent milestones reinforcing Nuance Pharma's commitment to the Chinese allergy market.In September 2025, the company entered into an exclusive long-term partnership with Stallergenes Greer for the development and registration of the company'sActair tablet in China, with Nuance Pharma retaining responsibility for subsequent commercialization. In January 2026,Actair received approval from the Pharmaceutical Administration Bureau of Macau. Most recently, in May 2026, Nuance Pharma launched Actair in China's Hainan Boao Pilot Zone through an early access program.Dr. Andreas Amrein, Chairman and Chief Executive Officer of Stallergenes Greer, added: \"This IND clearance is a significant achievement for our development partner, Nuance Pharma,","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/nuance-pharma-announces-ind-clearance-for-actair-pivotal-clinical-trial-in-china-302779685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4561","NUAN","IND","BK7095","BK4023","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380118","title":"Industrial Minerals Ltd-Response to ASX Aware Query","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637380118?lang=en_us&edition=fundamental","pubTime":"2026-05-21 13:36","pubTimestamp":1779341798,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUE1VLDTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IND.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636969608","title":"Industrial Minerals Ltd-Application for Quotation of Securities - Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2636969608","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636969608?lang=en_us&edition=fundamental","pubTime":"2026-05-20 09:17","pubTimestamp":1779239851,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUE8NKB5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636899893","title":"Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2636899893","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636899893?lang=en_us&edition=fundamental","pubTime":"2026-05-20 08:00","pubTimestamp":1779235200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, May 20, 2026 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that Dr. Bing Hou has been appointed Chief Scientific Officer, reporting directly to Dr. Jay Mei, Founder, Chairman, and Chief Executive Officer of Antengene.Dr. Hou's appointment underscores Antengene's commitment to strengthening its innovation-driven R&D model as a global biotech company. In this role, Dr. Hou will lead Antengene's efforts across Drug Discovery, Translational Medicine, and Chemistry, Manufacturing and Controls , with a focus on deepening the Company's research engine and building a pipeline of next-generation therapeutic candidates with transformational potential.\"I am honored and excited to step into the role of Chief Scient","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-appoints-dr-bing-hou-as-chief-scientific-officer-to-lead-innovation-driven-rd-strategy-and-advance-next-generation-pipeline-302776389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","IE00BKVL7J92.USD","LU2746668974.SGD","IE0031619046.USD","LU0882574139.USD","IE00B7SZL793.SGD","LU2237443465.HKD","LU1363072403.SGD","LU2237443549.SGD","DBB","LU0963586101.USD","CMC","LU0267386448.USD","BK4187","CRS","BK4080","ADC.AU","LU0149725797.USD","LU0170899867.USD","LU2746668461.USD","ADC","BK4231","LU2237443382.USD","BK4006","IE00BZ1G4Q59.USD","IND.AU","LU2237443895.HKD","IE00BFXG1179.USD","CRS.AU","LU2237443978.SGD","IE00B19Z4B17.USD","BK7095","IE00B66KJ199.SGD","IE00BHPRN162.USD","LU2237443622.USD","LU0971096721.USD","IE00B1BXHZ80.USD","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635272749","title":"Industrial Minerals To Acquire Drill Proven Gold Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2635272749","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635272749?lang=en_us&edition=fundamental","pubTime":"2026-05-13 14:12","pubTimestamp":1778652765,"startTime":"0","endTime":"0","summary":"May 13 (Reuters) - Industrial Minerals Ltd ::*IND TO ACQUIRE DRILL PROVEN GOLD PORTFOLIO*ACQUISITION VALUED AT A$4.67 MILLION IN SHARES WITH 2.0% NSR ROYALTY*CONDUCTING TWO-TRANCHE PLACEMENT OF UP TO ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nRSD2slTQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635227863","title":"BUZZ-Industrial Minerals at 7-month high on Laverton Gold Portfolio acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2635227863","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635227863?lang=en_us&edition=fundamental","pubTime":"2026-05-13 10:41","pubTimestamp":1778640087,"startTime":"0","endTime":"0","summary":"BUZZ-Industrial Minerals at 7-month high on Laverton Gold Portfolio acquisition** Shares of Industrial Minerals IND.AX rise as much as 6.1% to A$0.2, their highest level since September 2, 2025** On track to log its best session since April 27** Mineral explorer to acquire Laverton Gold Portfolio, consisting of 15 exploration licences covering about 205km** Portfolio located within highly prospective Laverton Tectonic Zone, one of Australia's premier orogenic gold districts** Additionally, co is conducting a two-tranche placement of up to A$3 million  to fund the Laverton Gold Project exploration programme, working capital** About 1.4 mln shares traded so far, 10.7x the 30-day avg** Up 34.6% YTD, including the session's moves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL6N41Q06A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND.AU","BK7104","FML.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221989","title":"Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221989","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635221989?lang=en_us&edition=fundamental","pubTime":"2026-05-13 08:00","pubTimestamp":1778630400,"startTime":"0","endTime":"0","summary":"CHENGDU, China, May 12, 2026 /PRNewswire/ --Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  announced that it has received a clinical trial notice from the Center for Drug Evaluation  of the National Medical Products Administration  approving the Investigational New Drug  application for PD-1 x VEGF bispecific antibody SKB118  for the treatment of advanced solid tumors.In December 2025, Kelun-Biotech and Crescent Biopharma  entered into a strategic collaboration for SKB118/CR-001. Under the collaboration, Crescent granted Kelun-Biotech exclusive rights to research, develop, manufacture and commercialize SKB118/CR-001 in Greater China . In January 2026, Crescent announced the regulatory clearance of the IND application for SKB118/CR-001 by the U.S. Food and Drug Administration  to initiate its global ASCEND Phase I/II clinical trial  for the treatment of locally advanced or metastatic solid tumors. The trial is ongoing and expected to initially enroll up to 290 patients.","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-receives-investigational-new-drug-approval-from-cde-for-skb118-a-pd-1-x-vegf-bispecific-antibody-302769694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1223082519.USD","LU1169589451.USD","IND.AU","BK4017","BK4581","LU1223082196.USD","BK4585","LU1169590202.USD","XBI","BK7095","CDE.AU","BK4588","IND","LU1223083913.SGD","BK4023","CDE","BK7050","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221846","title":"Industrial Minerals Ltd-Laverton Gold Project Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635221846?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:55","pubTimestamp":1778630119,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUE8FFL1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635322184","title":"Industrial Minerals Ltd - Acquisition Valued at a$4.67 Mln in Shares With 2.0% Nsr Royalty","url":"https://stock-news.laohu8.com/highlight/detail?id=2635322184","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635322184?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:54","pubTimestamp":1778630096,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUE2N49XY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IND.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221845","title":"Industrial Minerals Ltd - Conducting Two-Tranche Placement of up to a$3 Mln at a$0.10 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221845","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635221845?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:54","pubTimestamp":1778630096,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUE2N49XY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221837","title":"Industrial Minerals Ltd-Proposed Issue of Securities - Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635221837?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:54","pubTimestamp":1778630087,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUE58T4BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634241054","title":"BRIEF-Industrial Minerals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2634241054","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634241054?lang=en_us&edition=fundamental","pubTime":"2026-05-11 07:06","pubTimestamp":1778454412,"startTime":"0","endTime":"0","summary":"BRIEF-Industrial Minerals Seeks Trading HaltMay 11 (Reuters) - Industrial Minerals Ltd IND.AX:TRADING HALT PENDING PROPOSED ACQUISITION AND CAPITAL RAISING ANNOUNCEMENTFurther company coverage: IND.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nFWN41L1X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634424106","title":"Industrial Minerals Ltd - Trading Halt Pending Proposed Acquisition and Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2634424106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634424106?lang=en_us&edition=fundamental","pubTime":"2026-05-11 07:06","pubTimestamp":1778454387,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nFWN41L1X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628733305","title":"Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2628733305","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628733305?lang=en_us&edition=fundamental","pubTime":"2026-04-18 08:30","pubTimestamp":1776472200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, April 18, 2026 /PRNewswire/ -- Antengene Corporation Limited  , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that it has released present results from three novel programs in poster presentations at the 2026 American Association for Cancer Research Annual Meeting . The presentations will feature ATG-125 , an IO + ADC dual-function molecule being developed for the treatment of solid tumors, as well as two investigational T cell engagers  developed using the company's proprietary AnTenGager TCE platform, including ATG-106  for ovarian and kidney cancers, and ATG-112  for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC.","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-three-novel-programs-at-aacr-2026-highlighting-next-generation-adc-and-antengager-tces-302745781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","BK7095","CRS","CRS.AU","BK4006","IE00B66KJ199.SGD","IE00B19Z4B17.USD","IND.AU","LU2065731478.USD","IE0031619046.USD","ADC","BK4187","IE00B7SZL793.SGD","BK4080","BK4231","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626262186","title":"OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2626262186","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626262186?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:00","pubTimestamp":1775732400,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., April 9, 2026 /PRNewswire/ --OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant's dosing following the clearance of the Investigational New Drug  application for a Phase 1/2 clinical trial of ONC-841, the company's investigational Alzheimer's disease therapy by the National Medical Product Administration . The clinical trial registration number is CTR20260866.ONC-841 is the world's first and only clinical stage anti-SIGLEC 10 antibody. The drug was initially developed, and is in a Phase 2 trial, for patients with solid tumors. New preclinical research by OncoC4 has revealed ONC-841's novel activity in normalizing microglia's function in clearance of pathogenic protein aggregates in the brain . Benefitting from safety data from the oncology study, the new Phase 1/2 AD clinical trial received accelerated clearance to test the safety and clinical activity of the product for AD treatment.The first study participant was successful","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2787251/OncoC4_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2787251/OncoC4_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/oncoc4-announces-first-participants-dosing-in-phase-12-clinical-trial-of-onc-841-for-the-treatment-of-alzheimers-disease-302737593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4585","BK7095","BK4139","IND.AU","BK4588","ONC","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625493771","title":"Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2625493771","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625493771?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:00","pubTimestamp":1775559600,"startTime":"0","endTime":"0","summary":"-Fixed-dose combination of ASC30 and ASC39  tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study. The fixed dose combination had excellent oral bioavailability, drug exposure and a half-life of up to 12 hours. These data support ASC30_39 FDC tablets as a potential novel one-pill-once-daily therapy for obesity.-ASC30_39 FDC demonstrated excellent compatibility between ASC30 and ASC39 when combined together, with room temperature stability and a small pill size.-ASC30 is a Phase III-ready oral small molecule GLP-1R agonist that had a favorable gastrointestinalprofile with half the rate of vomiting vs. orforglipron, when both drugs are dosed with weekly titration.-ASC39, an oral small molecule amylin-selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.-Submission of an Investigational New Drug Application  to the U.S. Food and D","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2935737/Ascletis_Pharma_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2935737/Ascletis_Pharma_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-announces-fixed-dose-combination-of-asc30-once-daily-oral-small-molecule-glp-1r-agonist-and-asc39-once-daily-oral-small-molecule-amylin-selective-amylin-receptor-agonist-for-clinical-development-302735619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","BK4144","IND","GLP","BK7095","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":36,"code":"91000000","status":"200"}]}}